Literature DB >> 32509217

lncRNA NORAD promotes hepatocellular carcinoma progression via regulating miR-144-3p/SEPT2.

Qing Tian1,2, Xiaodong Yan3, Long Yang1,2, Zirong Liu1,2, Zheyue Yuan1,2,3, Zhongyang Shen1,2, Yamin Zhang1,2.   

Abstract

Non-coding RNA has been reported to be crucial regulator for cancer progression. This work was aimed to investigate the roles and associated mechanisms of non-coding RNA activated by DNA damage (NORAD) in hepatocellular carcinoma (HCC) progression. In this work, we explored the expression of NORAD, microRNA-144-3p (miR-144-3p), and septin 2 (SEPT2) in HCC tissues and cells. Effects of knockdown of ectopic of NORAD on HCC cell proliferation, colony formation, and apoptosis were explored. Rescue experiments were conducted to explore whether NORAD regulates HCC cell behaviors via the miR-144-3p/SEPT2 axis. Moreover, the effect of NORAD on HCC tumor progression in vivo was analyzed. We showed NORAD expression was elevated in both HCC tissues and cells. NORAD knockdown inhibits HCC cell growth but promotes apoptosis, while the overexpression of NORAD has opposite effects. Besides that, we found knockdown of NPRAD inhibits tumor growth. Moreover, we showed miR-144-3p expression was inversely correlated with NORAD and SEPT2, while NORAD and SEPT2 was positively correlated in HCC tissues. Functional assays showed NORAD functions as ceRNA through binding with miR-144-3p to regulate SEPT2 expression in HCC. Collectively, we showed NORAD serves as an oncogenic lncRNA to promote HCC progression via the miR-144-3p/SEPT2 axis. AJTR
Copyright © 2020.

Entities:  

Keywords:  NORAD; SEPT2; hepatocellular carcinoma; miR-144-3p

Year:  2020        PMID: 32509217

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  8 in total

1.  Upregulation of miR-144-3p protects myocardial function from ischemia-reperfusion injury through inhibition of TMEM16A Ca2+-activated chloride channel.

Authors:  Guoxun Yang; Xiao Tang; Ling Tan; Danpeng Nong; Peng Yang; Haien Ning
Journal:  Hum Cell       Date:  2021-01-15       Impact factor: 4.174

Review 2.  Interplay between endoplasmic reticulum stress and non-coding RNAs in cancer.

Authors:  Tianming Zhao; Juan Du; Hui Zeng
Journal:  J Hematol Oncol       Date:  2020-12-02       Impact factor: 17.388

3.  LINC00839/miR-144-3p/WTAP (WT1 Associated protein) axis is involved in regulating hepatocellular carcinoma progression.

Authors:  Xingqin Zhou; Yazhou Chang; Lirong Zhu; Chaoyan Shen; Jing Qian; Renan Chang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Human umbilical cord-mesenchymal stem cells-derived exosomes carrying microRNA-15a-5p possess therapeutic effects on Wilms tumor via regulating septin 2.

Authors:  He Huang; Peilin Zhong; Jianxing Zhang; Xinghe Chen; Jinwen Chen; Tian Lin; Qiang Wu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  High Expression of RRM1 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma.

Authors:  Guochao Mao; Changyou Shan; Weimiao Li; Baobao Liang; Li Ma; Shuqun Zhang
Journal:  Int J Gen Med       Date:  2022-03-06

6.  Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4.

Authors:  Khaoula Errafii; Neyla S Al-Akl; Olfa Khalifa; Abdelilah Arredouani
Journal:  J Transl Med       Date:  2021-06-02       Impact factor: 5.531

7.  Long non-coding RNA NORAD inhibition upregulates microRNA-323a-3p to suppress tumorigenesis and development of breast cancer through the PUM1/eIF2 axis.

Authors:  Pengfei Shi; Jiaming Zhang; Xun Li; Wenhuan Li; Hai Li; Peng Fu
Journal:  Cell Cycle       Date:  2021-06-14       Impact factor: 5.173

8.  JMJD2C-mediated long non-coding RNA MALAT1/microRNA-503-5p/SEPT2 axis worsens non-small cell lung cancer.

Authors:  Jun Zhang; Mingliang Wang; Jiashun Wang; Wendong Wang
Journal:  Cell Death Dis       Date:  2022-01-19       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.